Copy to clipboard 
The data below is based on reported sales from a subset of public orthopedic companies on a quarterly reporting schedule. These companies account for about two-thirds of the global market. I’m using this group as a proxy to measure quarterly market performance.
Orthopedic Market Data for Third Quarter 2025
Where applicable, company names for the current quarter are linked to a more detailed article containing highlights and segment and regional sales data.
Sales for consolidated half, nine months and full-year results are inclusive of all previously-reported data plus data from companies that have reported in the current quarter.
Segment Sales for Reporting Companies
| Segment | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $4,291.1 | $3,992.0 | $299.1 | 7.5% |
| Knees | $2,090.1 | $1,954.6 | $135.5 | 6.9% |
| Hips | $1,592.7 | $1,497.3 | $95.5 | 6.4% |
| Extremities | $608.3 | $540.2 | $68.1 | 12.6% |
| Spine | $1,097.9 | $1,002.8 | $95.1 | 9.5% |
| Trauma | $1,963.1 | $1,772.6 | $190.6 | 10.8% |
| Sports Medicine | $1,076.8 | $1,000.1 | $76.7 | 7.7% |
| Orthobiologics | $445.5 | $420.1 | $25.3 | 6% |
| Enabling Technology | $256.5 | $220.1 | $36.3 | 16.5% |
| Other | $834.3 | $672.3 | $162.1 | 24.1% |
| Total | $9,965.2 | $9,080.1 | $885.2 | 9.7% |
| Segment | 9m25 | 9m24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $13,071.4 | $12,420.9 | $650.6 | 5.2% |
| Knees | $6,387.4 | $6,126.9 | $260.5 | 4.3% |
| Hips | $4,837.5 | $4,617.7 | $219.8 | 4.8% |
| Extremities | $1,846.5 | $1,676.3 | $170.3 | 10.2% |
| Spine | $3,356.5 | $3,189.6 | $166.9 | 5.2% |
| Trauma | $5,798.1 | $5,309.3 | $488.9 | 9.2% |
| Sports Medicine | $3,162.0 | $3,014.8 | $147.1 | 4.9% |
| Orthobiologics | $1,311.3 | $1,250.6 | $60.6 | 4.8% |
| Enabling Technology | $716.5 | $684.3 | $32.2 | 4.7% |
| Other | $2,282.8 | $1,995.7 | $287.0 | 14.4% |
| Total | $29,698.5 | $27,865.2 | $1,833.3 | 6.6% |
Total Orthopedic Sales for Reporting Companies
| Company | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Anika Therapeutics | $26.1 | $27.2 | ($1.0) | (3.8%) |
| ATEC | $196.5 | $150.7 | $45.8 | 30.4% |
| Bioventus | $124.5 | $122.6 | $1.9 | 1.6% |
| BONESUPPORT | $32.4 | $26.1 | $6.2 | 23.8% |
| Carlsmed | $13.1 | $6.6 | $6.5 | 98.4% |
| CONMED | $138.2 | $130.5 | $7.7 | 5.9% |
| J&J MedTech | $2,272.5 | $2,189.8 | $82.7 | 3.8% |
| Enovis | $258.0 | $233.2 | $24.8 | 10.6% |
| Globus Medical | $769.0 | $625.7 | $143.3 | 22.9% |
| Orthofix | $205.6 | $196.6 | $9.0 | 4.6% |
| OrthoPediatrics | $52.6 | $47.0 | $5.5 | 11.8% |
| Shoulder Innovations | $11.8 | $7.5 | $4.3 | 57.7% |
| SI-BONE | $48.7 | $40.3 | $8.3 | 20.6% |
| Smith+Nephew | $988.8 | $935.0 | $53.8 | 5.8% |
| Stryker | $2,720.2 | $2,427.3 | $292.8 | 12.1% |
| Treace Medical | $50.2 | $45.1 | $5.1 | 11.4% |
| Vericel | $55.7 | $44.7 | $11.0 | 24.6% |
| Zimmer Biomet | $2,001.4 | $1,824.1 | $177.3 | 9.7% |
| Company | 9m25 | 9m24 | $ Chg | % Chg |
|---|---|---|---|---|
| Anika Therapeutics | $77.4 | $82.9 | ($5.5) | (6.6%) |
| ATEC | $551.2 | $434.8 | $116.5 | 26.8% |
| Bioventus | $370.5 | $360.9 | $9.6 | 2.7% |
| BONESUPPORT | $94.8 | $70.6 | $24.2 | 34.3% |
| Carlsmed | $35.3 | $17.8 | $17.6 | 99.1% |
| CONMED | $417.2 | $405.0 | $12.2 | 3% |
| J&J MedTech | $6,818.8 | $6,842.2 | ($23.5) | (0.3%) |
| Enovis | $818.2 | $737.8 | $80.4 | 10.9% |
| Globus Medical | $2,112.5 | $1,862.1 | $250.4 | 13.5% |
| Orthofix | $602.4 | $583.8 | $18.6 | 3.2% |
| OrthoPediatrics | $150.6 | $131.2 | $19.3 | 14.7% |
| Shoulder Innovations | $32.9 | $22.9 | $10.0 | 43.7% |
| SI-BONE | $144.6 | $118.2 | $26.4 | 22.3% |
| Smith+Nephew | $2,998.1 | $2,870.8 | $127.3 | 4.4% |
| Stryker | $8,180.6 | $7,399.4 | $781.2 | 10.6% |
| Treace Medical | $150.2 | $140.6 | $9.5 | 6.8% |
| Vericel | $155.4 | $129.0 | $26.4 | 20.5% |
| Zimmer Biomet | $5,987.9 | $5,655.3 | $332.6 | 5.9% |
Orthopedic Market Developments for Third Quarter 2025
ATEC Taking Share from All Major Competitors
“You don’t grow $40-plus million year-over-year without kind of touching all the competitors,” said ATEC CEO Todd Koning.
CONMED Turning the Corner on Supply
Supply constraints for orthopedic products has been an ongoing headwind for the company, but CONMED made progress throughout 2025. Company leadership stopped short of declaring victory, but said they were in the later innings of dealing with the supply headwinds.
Enovis Has Many Weapons in Extremity Segment
The ARG (augmented reverse glenoid) system continues to gain traction for Enovis while still early in its release cycle. The company has additional products in its innovation pipeline to support continued growth in extremities. Enovis’ shoulder (and knee) business will get a further boost in the first half of next year with a broader release of the ARVIS platform.
Globus Demonstrates Strength in U.S. Spine
The company has put together 32 weeks of consecutive sales growth for U.S. spine sales, with balanced contributions coming from all tracked product categories. U.S. spine sales grew 9.6% in the third quarter, with momentum carrying into the fourth quarter.
J&J MedTech to Spin Off DePuy Synthes
Along with its third-quarter earnings, J&J MedTech announced its intent to separate its orthopedics business into a standalone company named DePuy Synthes within the next two years. Namal Nawana is slated to serve as Worldwide President of the entity.
Orthofix Hits Fifth Straight Quarter of Double Digit Trauma Growth in U.S.
The company has put together 32 weeks of consecutive sales growth for U.S. spine sales, with balanced contributions coming from all tracked product categories. U.S. spine sales grew 9.6% in the third quarter, with momentum carrying into the fourth quarter.
Mako Remains Significant Growth Driver for Stryker
The company saw the most Mako placements ever for a third quarter and a higher than usual number of outright purchases, leading to the tremendous enabling technology growth rate seen this quarter.
Treace Downgrades Guidance on Volume Headwinds
The company’s survey of its surgeons indicated a 7% volume decline year-over-year as patients defer elective procedures, especially those with commercial insurance.
Zimmer Biomet Drives Better U.S. Performance.
The company’s U.S. sales growth accelerated from 2.3% in the second quarter to 5.6% this quarter. It represents the best U.S. growth performance for the company since mid-2023.
The data below is based on reported sales from a subset of public orthopedic companies on a quarterly reporting schedule. These companies account for about two-thirds of the global market. I’m using this group as a proxy to measure quarterly market performance.
Orthopedic Market Data for Third Quarter 2025
Where applicable, company names...
The data below is based on reported sales from a subset of public orthopedic companies on a quarterly reporting schedule. These companies account for about two-thirds of the global market. I’m using this group as a proxy to measure quarterly market performance.
Orthopedic Market Data for Third Quarter 2025
Where applicable, company names for the current quarter are linked to a more detailed article containing highlights and segment and regional sales data.
Sales for consolidated half, nine months and full-year results are inclusive of all previously-reported data plus data from companies that have reported in the current quarter.
Segment Sales for Reporting Companies
| Segment | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $4,291.1 | $3,992.0 | $299.1 | 7.5% |
| Knees | $2,090.1 | $1,954.6 | $135.5 | 6.9% |
| Hips | $1,592.7 | $1,497.3 | $95.5 | 6.4% |
| Extremities | $608.3 | $540.2 | $68.1 | 12.6% |
| Spine | $1,097.9 | $1,002.8 | $95.1 | 9.5% |
| Trauma | $1,963.1 | $1,772.6 | $190.6 | 10.8% |
| Sports Medicine | $1,076.8 | $1,000.1 | $76.7 | 7.7% |
| Orthobiologics | $445.5 | $420.1 | $25.3 | 6% |
| Enabling Technology | $256.5 | $220.1 | $36.3 | 16.5% |
| Other | $834.3 | $672.3 | $162.1 | 24.1% |
| Total | $9,965.2 | $9,080.1 | $885.2 | 9.7% |
| Segment | 9m25 | 9m24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $13,071.4 | $12,420.9 | $650.6 | 5.2% |
| Knees | $6,387.4 | $6,126.9 | $260.5 | 4.3% |
| Hips | $4,837.5 | $4,617.7 | $219.8 | 4.8% |
| Extremities | $1,846.5 | $1,676.3 | $170.3 | 10.2% |
| Spine | $3,356.5 | $3,189.6 | $166.9 | 5.2% |
| Trauma | $5,798.1 | $5,309.3 | $488.9 | 9.2% |
| Sports Medicine | $3,162.0 | $3,014.8 | $147.1 | 4.9% |
| Orthobiologics | $1,311.3 | $1,250.6 | $60.6 | 4.8% |
| Enabling Technology | $716.5 | $684.3 | $32.2 | 4.7% |
| Other | $2,282.8 | $1,995.7 | $287.0 | 14.4% |
| Total | $29,698.5 | $27,865.2 | $1,833.3 | 6.6% |
Total Orthopedic Sales for Reporting Companies
| Company | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Anika Therapeutics | $26.1 | $27.2 | ($1.0) | (3.8%) |
| ATEC | $196.5 | $150.7 | $45.8 | 30.4% |
| Bioventus | $124.5 | $122.6 | $1.9 | 1.6% |
| BONESUPPORT | $32.4 | $26.1 | $6.2 | 23.8% |
| Carlsmed | $13.1 | $6.6 | $6.5 | 98.4% |
| CONMED | $138.2 | $130.5 | $7.7 | 5.9% |
| J&J MedTech | $2,272.5 | $2,189.8 | $82.7 | 3.8% |
| Enovis | $258.0 | $233.2 | $24.8 | 10.6% |
| Globus Medical | $769.0 | $625.7 | $143.3 | 22.9% |
| Orthofix | $205.6 | $196.6 | $9.0 | 4.6% |
| OrthoPediatrics | $52.6 | $47.0 | $5.5 | 11.8% |
| Shoulder Innovations | $11.8 | $7.5 | $4.3 | 57.7% |
| SI-BONE | $48.7 | $40.3 | $8.3 | 20.6% |
| Smith+Nephew | $988.8 | $935.0 | $53.8 | 5.8% |
| Stryker | $2,720.2 | $2,427.3 | $292.8 | 12.1% |
| Treace Medical | $50.2 | $45.1 | $5.1 | 11.4% |
| Vericel | $55.7 | $44.7 | $11.0 | 24.6% |
| Zimmer Biomet | $2,001.4 | $1,824.1 | $177.3 | 9.7% |
| Company | 9m25 | 9m24 | $ Chg | % Chg |
|---|---|---|---|---|
| Anika Therapeutics | $77.4 | $82.9 | ($5.5) | (6.6%) |
| ATEC | $551.2 | $434.8 | $116.5 | 26.8% |
| Bioventus | $370.5 | $360.9 | $9.6 | 2.7% |
| BONESUPPORT | $94.8 | $70.6 | $24.2 | 34.3% |
| Carlsmed | $35.3 | $17.8 | $17.6 | 99.1% |
| CONMED | $417.2 | $405.0 | $12.2 | 3% |
| J&J MedTech | $6,818.8 | $6,842.2 | ($23.5) | (0.3%) |
| Enovis | $818.2 | $737.8 | $80.4 | 10.9% |
| Globus Medical | $2,112.5 | $1,862.1 | $250.4 | 13.5% |
| Orthofix | $602.4 | $583.8 | $18.6 | 3.2% |
| OrthoPediatrics | $150.6 | $131.2 | $19.3 | 14.7% |
| Shoulder Innovations | $32.9 | $22.9 | $10.0 | 43.7% |
| SI-BONE | $144.6 | $118.2 | $26.4 | 22.3% |
| Smith+Nephew | $2,998.1 | $2,870.8 | $127.3 | 4.4% |
| Stryker | $8,180.6 | $7,399.4 | $781.2 | 10.6% |
| Treace Medical | $150.2 | $140.6 | $9.5 | 6.8% |
| Vericel | $155.4 | $129.0 | $26.4 | 20.5% |
| Zimmer Biomet | $5,987.9 | $5,655.3 | $332.6 | 5.9% |
Orthopedic Market Developments for Third Quarter 2025
ATEC Taking Share from All Major Competitors
“You don’t grow $40-plus million year-over-year without kind of touching all the competitors,” said ATEC CEO Todd Koning.
CONMED Turning the Corner on Supply
Supply constraints for orthopedic products has been an ongoing headwind for the company, but CONMED made progress throughout 2025. Company leadership stopped short of declaring victory, but said they were in the later innings of dealing with the supply headwinds.
Enovis Has Many Weapons in Extremity Segment
The ARG (augmented reverse glenoid) system continues to gain traction for Enovis while still early in its release cycle. The company has additional products in its innovation pipeline to support continued growth in extremities. Enovis’ shoulder (and knee) business will get a further boost in the first half of next year with a broader release of the ARVIS platform.
Globus Demonstrates Strength in U.S. Spine
The company has put together 32 weeks of consecutive sales growth for U.S. spine sales, with balanced contributions coming from all tracked product categories. U.S. spine sales grew 9.6% in the third quarter, with momentum carrying into the fourth quarter.
J&J MedTech to Spin Off DePuy Synthes
Along with its third-quarter earnings, J&J MedTech announced its intent to separate its orthopedics business into a standalone company named DePuy Synthes within the next two years. Namal Nawana is slated to serve as Worldwide President of the entity.
Orthofix Hits Fifth Straight Quarter of Double Digit Trauma Growth in U.S.
The company has put together 32 weeks of consecutive sales growth for U.S. spine sales, with balanced contributions coming from all tracked product categories. U.S. spine sales grew 9.6% in the third quarter, with momentum carrying into the fourth quarter.
Mako Remains Significant Growth Driver for Stryker
The company saw the most Mako placements ever for a third quarter and a higher than usual number of outright purchases, leading to the tremendous enabling technology growth rate seen this quarter.
Treace Downgrades Guidance on Volume Headwinds
The company’s survey of its surgeons indicated a 7% volume decline year-over-year as patients defer elective procedures, especially those with commercial insurance.
Zimmer Biomet Drives Better U.S. Performance.
The company’s U.S. sales growth accelerated from 2.3% in the second quarter to 5.6% this quarter. It represents the best U.S. growth performance for the company since mid-2023.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
